[Form 4] Organogenesis Holdings Inc. Insider Trading Activity

Rhea-AI Filing Summary

Organogenesis Holdings Inc. (ORGO) insider activity: A director and 10% owner reported Form 4 transactions. An affiliated trust purchased 251,001 shares of Class A common stock on 05/14/2025 at a weighted-average price of $3.0878 and 107,494 shares on 05/15/2025 at a weighted-average price of $2.9862. The same trust sold 4,156 shares on 06/09/2025 at a weighted-average price of $3.5003 and 18,620 shares on 06/10/2025 at a weighted-average price of $3.5583.

Following the reported transactions, holdings included 335,719 shares indirectly by the Glenn Nussdorf 10 Year Follow On Trust and 3,065,591 shares held directly. The filing notes that the sales on 06/09/2025 and 06/10/2025 were matchable with a 05/15/2025 purchase under Section 16(b), and the reporting person paid the issuer $13,285.24, comprising $12,971.78 in profit plus $313.46 in interest.

Insights

Equity Governance Analyst

Insider with 10% stake made small buy/sell trades and remitted short-swing profits to the company.

A director and 10% owner of Organogenesis Holdings Inc. (ORGO) reported multiple Class A purchases on 05/14/2025 and 05/15/2025 and smaller sales on 06/09/2025 and 06/10/2025. The reported trades for one trust were 251,001 shares at a weighted average of $3.0878 (range $3.00-$3.10) and 107,494 shares at $2.9862 (range $2.9725-$3.00), followed by sales of 4,156 shares at $3.5003 (range $3.50-$3.505) and 18,620 shares at $3.5583 (range $3.55-$3.59).

Post-trade holdings include indirect ownership of 335,719 shares in the Glenn Nussdorf 10 Year Follow On Trust (after the sales), plus additional positions reported as 3,065,591 (direct), 918,680 (indirect via GN 2016 Family Trust), and 7,928,570 (indirect via GN 2016 Organo 10‑Year GRAT). The filer identified the short-swing pairing between the May 15 purchase and June 9–10 sales and paid the issuer $13,285.24 (profit of $12,971.78 plus interest of $313.46 at 6% per annum).

This signals compliance with Section 16(b) and clarifies current insider ownership across multiple vehicles. Items to watch: any continued changes in these trust and direct positions over the next filings, and any further Section 16(b) recoveries if additional matched trades occur.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NUSSDORF GLENN H

(Last) (First) (Middle)

35 SAWGRASS DRIVE

(Street)

BELLPORT NY 11713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/14/2025		P		251,001	A	$3.0878(1)	251,001	I	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998
Class A Common Stock	05/15/2025		P		107,494	A	$2.9862(2)	358,495	I	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998
Class A Common Stock	06/09/2025		S(5)		4,156	D	$3.5003(3)	354,339	I	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998
Class A Common Stock	06/10/2025		S(5)		18,620	D	$3.5583(4)	335,719	I	By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998
Class A Common Stock								3,065,591	D
Class A Common Stock								918,680	I	By GN 2016 Family Trust u/a/d August 12, 2016
Class A Common Stock								7,928,570	I	By GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

2. The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

5. The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46).

	/s/ William R. Kolb, Attorney-in-Fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.